VEG-HM465-100μg / 询价
VEG-HM465-500μg / 询价
VEG-HM465-500μgx2 / 询价
Human VEGF165 Protein
Recombinant Human VEGF165 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Ala27-Arg191 [Accession | P15692-4].
The protein has a predicted MW of 22.2 kDa. Due to glycosylation, the protein migrates to 28-35 kDa under reduced (R) condition, 45-60 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
>95% as determined by Bis-Tris PAGE
Less than 1 EU per μg by the LAL method.
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human VEGF165 on Bis-Tris PAGE under reduced (R) condition and Non reducing (N) condition. The purity is greater than 95%.
Immobilized Human VEGF165 at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-VEGF165 Antibody, hFc Tag with the EC50 of 4.1 ng/ml determined by ELISA (QC Test).
Immobilized Human VEGF165, His Tag at 1μg/ml(100μl/well) on the plate. Dose response curve for Human VEGF R1, hFc Tag with the EC50 of 46.8ng/ml determined by ELISA.
Immobilized Human VEGF165, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Human VEGF R2, hFc Tag with the EC50 of 7.8ng/ml determined by ELISA.
Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189.
VEGF; VEGFA; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609;VEGF-165
(1) Rosen, L. S. VEGF-Targeted Therapy: Therapeutic Potential and Recent Advances[J]. The Oncologist, 2005, 10(6):382-391.
